Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Pharmacogenetics of Major Depressive Disorder: Top Genes and Pathways Toward Clinical Applications
Ist Teil von
Current psychiatry reports, 2015-07, Vol.17 (7), p.50-50, Article 50
Ort / Verlag
New York: Springer US
Erscheinungsjahr
2015
Link zum Volltext
Quelle
Alma/SFX Local Collection
Beschreibungen/Notizen
The pharmacogenetics of antidepressants has been not only a challenging but also frustrating research field since its birth in the 1990s. Indeed, great expectations followed the first evidence of familiar aggregation of antidepressant response. Despite the progress from candidate gene studies to genome-wide association studies (GWAS), results fell out the expectations and they were often inconsistent. Anyway, the cumulative evidence supports the involvement of some genes and molecular pathways in antidepressant efficacy. The best single genes are
SLC6A4
,
HTR2A
,
BDNF
,
GNB3
,
FKBP5
,
ABCB1
, and cytochrome P450 genes (
CYP2D6
and
CYP2C19
). Molecular pathways involved in inflammation and neuroplasticity show the greatest support. The first studies evaluating benefits of genotype-guided antidepressant treatments provided encouraging results and confirmed the relevance of
SLC6A4
,
HTR2A
,
ABCB1
, and cytochrome P450 genes. Further progress in genotyping and data analysis would allow to move forward and complete the understanding of antidepressant pharmacogenetics and its translation into clinical applications.